<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Cetuximab, a chimeric monoclonal antibody to epidermal growth factor receptor, is an effective chemotherapeutic agent for patients with <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Whereas several specific adverse reactions to cetuximab such as <z:hpo ids='HP_0000988'>skin rash</z:hpo> and nail toxicity have been reported, there have been few reports of <z:e sem="disease" ids="C1112565" disease_type="Disease or Syndrome" abbrv="">pneumatosis intestinalis</z:e> related to cetuximab-containing chemotherapy </plain></SENT>
<SENT sid="2" pm="."><plain>We describe here three patients with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> who developed <z:e sem="disease" ids="C1112565" disease_type="Disease or Syndrome" abbrv="">pneumatosis intestinalis</z:e> during treatment with cetuximab-containing chemotherapy, which developed after 7, 19 and 47 weeks of cetuximab treatment, and discovered on routine follow-up computed tomographic scans for response evaluations </plain></SENT>
<SENT sid="3" pm="."><plain>None of these patients complained of <z:hpo ids='HP_0002027'>abdominal pain</z:hpo>, showed signs of peritoneal irritation on physical examination or had elevated serum concentrations of <z:hpo ids='HP_0011009'>acute</z:hpo> inflammatory markers </plain></SENT>
<SENT sid="4" pm="."><plain>Following cessation of cetuximab and conservative medical treatment, <z:hpo ids='HP_0000001'>all</z:hpo> three patients showed complete resolution of <z:e sem="disease" ids="C1112565" disease_type="Disease or Syndrome" abbrv="">pneumatosis intestinalis</z:e> on abdominal pelvic computed tomographic scans </plain></SENT>
</text></document>